Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and immunogenicity of modified-process recombinant hepatitis B vaccine in healthy adults ≥50 years
2006-003649-18Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by Merck & Co. Primary endpoints: Seroprotection rate one month after third dose (modified-process vaccine) and Seroprotection rate one month after third dose (ENGERIX-B). Started Nov 2006; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-003649-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003649-18.